Table 3.
Retrospective Analysis of Salvage Autologous HCT Outcomes (Series with More Than 40 Patients)
| Ref | n | NRM (%) | Median PFS in Months | Prognostic Factor |
|---|---|---|---|---|
| [32] | 44 | 2 | 12 | First RD |
| [33] | 81 | 3 | 16 | First RD, ≥VGPR |
| [34] | 41 | 7 | 8.5 | Age > 65, lines of therapy |
| [35] | 55 | 5 | 14 | First RD |
| [36] | 83 | NS | 15.6 | NS |
| [37] | 60 | NS | 11 | NS |
| [38] | 98 | 4 | 10.3 | First RD |
| [39] | 187 | 2 | 11 | First RD |
| [40] | 200 | 3 | 15 | First RD, reinduction with novel drugs and response, ISS at salvage autologous HCT |
| [41] | 111 | NS | 18 | Improved outcomes for second HCT when compared with IMiDs and proteasome inhibitors, stage, hemoglobin |
RD indicates remission duration; VGPR, very good partial response.